Business Context and Reporting Period
This Form 8-K filing by Corbus Pharmaceuticals Holdings, Inc. reports on the Annual Meeting of Stockholders held on May 24, 2018. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes or operational updates were disclosed in this filing. The primary event was the successful ratification of the board of directors and the independent auditor.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies. It strictly details the outcomes of the shareholder vote.
Important Facts for Investors
- Director Election: All five nominees (Dr. Yuval Cohen, Alan Holmer, David P. Hochman, Avery W. Catlin, and Paris Panayiotopoulos) were elected to one-year terms.
- Auditor Ratification: The appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018, was approved.
- Voting Participation: There were significant broker non-votes (33,979,846) regarding the election of directors, while the auditor ratification had zero broker non-votes.
- Vote Counts: The auditor ratification received 45,710,699 votes for, 313,566 against, and 873,192 abstentions.